From a therapeutic perspective, our previous work has demonstrated that antibodies targeting agrin reduced oncogenic signaling and tumor growth in vivo, highlighting agrin’s potential as a therapeutic target for antibody therapy in HCC. The gene discussed is AGRN; the disease is hepatocellular carcinoma.